After both renal and hepatic evaluations, it was concluded that no hepatic or renal dosing adjustments are necessary with liraglutide
Research comparing individuals with type 2 diabetes to healthy controls demonstrated that this hormone enhances insulin secretion in a dose-dependent manner
One randomized, controlled trial from 2021 found that liraglutide reduced major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, by 13 percent compared to placebo in patients with type 2 diabetes at high cardiovascular risk
Another approved use for Ozempic is to reduce the risk of major cardiovascular disease, like heart attack or stroke, in adults with type 2 diabetes with known heart disease
These companies currently offer five GLP-1 drugs approved for type 2 diabetes, with four also approved for various cardiovascular conditions